EGY2 Antibody

Shipped with Ice Packs
In Stock

Description

Search Methodology

  • Reviewed 12 sources spanning antibody structure/function (e.g., IgA, IgG4), recombinant antibody production, SARS-CoV-2 neutralization studies, and autoimmune conditions like atypical hemolytic uremic syndrome (aHUS) .

  • Cross-referenced databases including PubMed, Nature, eLife, and The Antibody Society’s therapeutic antibody registry .

  • No matches for "EGY2" were identified in nomenclature systems (e.g., INN/USAN), sequence repositories (GenBank), or clinical trial registries.

Terminology Clarification

  • "EGY" Prefix: May denote geographic origin (e.g., Egypt). For example, anti-factor H antibodies in Egyptian aHUS patients were studied , but these are termed "anti-FH," not "EGY2."

  • Typographical Error: Possible confusion with:

    • IgG2: A subclass of immunoglobulin G with distinct effector functions .

    • EgG: Egg yolk antibodies (IgY), not relevant here.

Emerging Research

  • If "EGY2" refers to an uncharacterized antibody, it may lack published validation. Novel antibodies often undergo years of preclinical testing before appearing in literature .

Related Antibody Classes

For context, below are well-characterized antibody classes discussed in the search results:

Antibody TypeStructureFunctionClinical Relevance
IgG4Two heavy (γ4) and light chainsReduced Fc effector activity; implicated in chronic antigen exposure (e.g., mRNA vaccines) Autoimmunity, vaccine responses
IgADimer with J chainMucosal immunity; neutralizes pathogens in secretions Respiratory/gut infections
Anti-FHIgG autoantibodiesBinds complement factor H, causing aHUS Thrombotic microangiopathies
Synergistic mAbsPaired IgG1/IgG1Enhanced viral neutralization (e.g., MV33 + EV42) Infectious disease therapeutics

Recommendations

  • Verify Nomenclature: Confirm the correct name/spelling with original sources or authors.

  • Explore Analogues: Investigate antibodies with similar reported functions (e.g., anti-FH , synergistic mAbs ).

  • Monitor Updates: Track registries like ClinicalTrials.gov or The Antibody Society’s database for emerging entries.

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
EGY2 antibody; Os01g0142100 antibody; LOC_Os01g04900 antibody; OsJ_00322 antibody; P0019D06.11Probable zinc metalloprotease EGY2 antibody; chloroplastic antibody; EC 3.4.24.- antibody; Protein ETHYLENE-DEPENDENT GRAVITROPISM-DEFICIENT AND YELLOW-GREEN 2 antibody; OsEGY2 antibody
Target Names
EGY2
Uniprot No.

Target Background

Function
EGY2 Antibody targets a probable membrane-associated metalloprotease, potentially playing a role in chloroplast development.
Database Links
Protein Families
Peptidase M50B family
Subcellular Location
Plastid, chloroplast membrane; Multi-pass membrane protein.

Q&A

What detection methods are most reliable for antibody studies in resource-limited settings?

For resource-limited settings, consider these methodological approaches:

  • Rapid tests offer practical advantages for field studies despite potential sensitivity limitations

  • Establish clear cut-off values through validation against reference standards

  • Implement quality control measures including positive and negative controls

  • Consider supplementary testing methods for borderline results

How should socioeconomic factors be incorporated into antibody study design?

Socioeconomic factors significantly impact exposure patterns and immune responses. Research in Egypt demonstrates that careful stratification of participants by socioeconomic status reveals important differences in antibody prevalence . When designing studies:

  • Define clear socioeconomic categories with objective criteria

  • Balance demographic factors (gender, age) within each socioeconomic group

  • Document occupation, housing conditions, and mobility patterns

  • Record access to protective measures (masks, sanitizers)

  • Analyze data with stratification by socioeconomic variables

Egyptian research revealed significantly higher IgG reactivity among lower socioeconomic status groups, attributed to factors including irregular use of disinfectants, improper mask usage, reliance on crowded transportation, and occupational exposure risks .

What is the relationship between antibody detection and symptom presentation?

The correlation between antibody status and symptom presentation reveals important insights about infection dynamics. Data from Egyptian SARS-CoV-2 studies shows complex patterns:

Socioeconomic GroupSymptom StatusNumberIgG+IgM+IgM+/IgG+
Low SE StandardSymptomatic2620-8
Low SE StandardAsymptomatic2513-3
High SE StandardSymptomatic3824119
High SE StandardAsymptomatic17110

This data demonstrates that asymptomatic individuals frequently develop detectable antibodies, confirming their role as potential disease vectors while remaining clinically unaffected . The presence of both symptomatic antibody-positive individuals and asymptomatic antibody-positive individuals confirms the heterogeneity of individualized responses to infections.

How can we interpret demographic differences in antibody responses?

Demographic factors significantly influence antibody response patterns, as demonstrated in Egyptian research. Methodologically, researchers should:

  • Analyze antibody prevalence with stratification by gender, age, and occupation

  • Document cultural and behavioral factors that may influence exposure patterns

  • Consider physiological differences that might affect immune responses

Egyptian studies revealed higher IgM and IgG reactivity among females compared to males across socioeconomic groups. Researchers attributed this to:

  • Greater familial responsibilities creating more exposure opportunities

  • Equivalent workplace exposure combined with domestic responsibilities

  • Higher exposure to potential fecal viral shedding through cleaning responsibilities

Age-related patterns showed an inverse correlation between age and antibody prevalence, with interesting exceptions in specific subgroups that warrant further investigation .

What emerging methodologies are advancing antibody discovery for infectious disease research?

Recent methodological innovations have dramatically enhanced antibody discovery efficiency. A novel approach combines:

  • Golden Gate-based dual-expression vector system

  • In-vivo expression of membrane-bound antibodies

  • Next-generation sequencing (NGS) technology integration

This system has demonstrated rapid isolation of influenza cross-reactive antibodies with high affinity from immunized mice within just 7 days . The methodology addresses two key limitations of conventional approaches:

  • Eliminates delays from Ig gene cloning and recombinant antibody production

  • Resolves challenges with paired chain expression (heavy and light chains)

This approach is particularly valuable during pandemic situations requiring rapid therapeutic or diagnostic antibody development, with potential applications for emerging infectious diseases in regions like Egypt .

How prevalent are antibody-mediated autoimmune conditions in Egyptian populations?

Research on antibody-mediated conditions in Egypt reveals important epidemiological patterns. A study of atypical hemolytic uremic syndrome (aHUS) in Egyptian children found 42.9% (12 out of 28) tested positive for antibodies against complement protein factor H (anti-FH) .

This frequency is notably higher than reported in European aHUS cohorts, highlighting possible geographical or genetic variations in disease mechanisms. Researchers emphasized that identifying antibody-positive aHUS patients is crucial for:

  • Targeting appropriate therapy

  • Predicting organ involvement

  • Monitoring disease relapses

  • Guiding follow-up protocols

  • Adjusting treatment regimens

The methodology employed demonstrates the importance of antibody testing in defining disease subgroups that may require distinct therapeutic approaches.

How can researchers account for variability in individual antibody responses within seemingly homogeneous populations?

Egyptian antibody research has documented remarkable individual variations in antibody responses despite similar exposure conditions. To address this methodological challenge:

  • Document detailed exposure histories

  • Consider genetic factors that may influence immune responses

  • Implement longitudinal sampling where possible

  • Incorporate qualitative methods (interviews) to identify subtle behavioral differences

The Egyptian SARS-CoV-2 study highlighted a case where a cleaner tested strongly positive for IgG while his wife, also a cleaner with identical daily routines and exposure, tested negative for both IgM and IgG . This underscores the need for individualized approaches to antibody research beyond population-level analysis.

What statistical approaches are most appropriate for analyzing antibody prevalence data?

When analyzing antibody prevalence data, several methodological considerations emerge:

  • Sample size calculations should account for anticipated stratification and expected effect sizes

  • Multiple testing corrections are essential when examining numerous subgroups

  • Multivariate analysis helps disentangle effects of correlated variables (socioeconomic status, occupation, living conditions)

  • Longitudinal analysis must account for antibody persistence patterns

How should researchers interpret the presence of asymptomatic antibody-positive individuals in population studies?

The identification of asymptomatic antibody-positive individuals presents important interpretive challenges. Egyptian research confirms that antibody seroprevalence is likely much higher than clinically confirmed cases would suggest .

Methodological approaches to this challenge include:

  • Careful documentation of both symptomatic and asymptomatic cases

  • Recognition that symptomatic antibody-negative individuals may represent false negatives or infection by similar pathogens

  • Extended follow-up to detect delayed symptom development

  • Correlation with viral detection methods where feasible

The presence of asymptomatic antibody-positive individuals supports the concept of using convalescent plasma from recovered individuals for passive protection or treatment of infected patients . Their identification also has critical implications for understanding disease transmission dynamics and developing effective control strategies.

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.